ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

First data with adjuvant ribociclib

More CDK4/6 options for EBC patients

From PENELOPE-B to SURVIVE

Palbociclib after Palbociclib might not be the best option

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

1/3 of patients with HER2+ in future without chemotherapy?

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

Ribociclib improves iDFS

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

TILs are prognostic but not predictive in HER2+ EBC

TILs in HER2+ disease - prognostic, but not enough to deescalate

SOC of ovarian ablation confirmed in meta-analysis.

De-escalation of CT for early BC

Early follow-up shows clear benefit

Discussions on CDK4/6 inhibitors in EBC

Response adapted, chemotherapy-free option in HER2+ EBC

My EBC highlights from ASCO23

Ribociclib has arrived in the adjuvant setting

Another proof of efficacy of immunotherapy in advanced TNBC

Can we preserve our patients form chemotherapy?

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

Young patients benefit from ovarian suppression

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

A challenge for clinical management

Ovarian function - Ovarian suppression not necessary in young patients?

10 years update on ShortHER

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Practice changing or not quite yet?

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

NATALEE nicht überraschend aber überzeugend positiv

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Eine Herausforderung für viele Patienten, wenig Doktoren

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

Palbociclib después de Palbociclib podría no ser la mejor opción

Czy wystarczy, aby zmienić standardy?

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Von PENELOPE-B zur SURVIVE

Eine Herausforderung für das klinische Management

Primele date cu ribociclib adjuvant

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

I miei punti salienti di ASCO23

What is the optimal therapie sequence for HR+ MBC patients?

E-Health Applications in Oral Cancer Therapy

The start of precision medicine in HR+ breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

Continued OS benefit for Sacituzumab Govitecan

Mises à jour sur les ADC dans le cancer du sein métastatique

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

The value of eHealth

Update ADC efficacy

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

CDK4/6i in first line and beyond & Biomarkers

Confirming results for PARPi in mCRPC

Reassuring real-world data!

Part 1: Important update on testosterone-recovery

Metastasis-directed for prostate cancer

PEACE 1 - results and controversies

LuPARP combination study: LuPSMA and Olaparib in mCRPC

ARASEC: ADT + Daralutamide for mHSPC

AI for prediction in local prostate carcinoma

Intensified or de-intensified therapy in mHSPC

TALAPRO-2: Results and controversies

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

Part2: Important update on testosterone-recovery

Over-staging of bone scan compared with PSMA PET/CT

PAPR-inhibitors: Patient-selection matters!

DEAR trial: real-world comparator analyses of ARIs

PRL-02: Intramuscular arbiraterone

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Intensifierad eller de-intensifierad behandling vid mHSPC?

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PARP-inhibitors: La selección de pacientes es importante

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

What is your preferred sequence in 1st line treatment and how you treat after progress?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

FGFR inhibition

New SoC option for metastatic bladder cancer

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Extent of lymphadenectomy in cystectomy

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

New standard for MIBC

Targeted therapies in advanced urothelial cancer: The renaissance?!

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Nouvelles options de soins standard pour le cancer de la vessie métastatique

The efficacy of FGFR targeting

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

Update EV/Pembro, Avelumab Maintenance

The impact of microbiome and supplements on therapy efficacy

Non ccRCC: how should we treat patients today?

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

Update and take home message of 1st Line mRCC

New standard for 2nd line RCC?

1st Line therapy RCC: which combination to choose?

Long-term follow-up for IO/TKI in mRCC

New data non ccRCC

News from the adjuvant

IO rechallenge in mRCC

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Adjuvant IO in KRASm patients

Confirmation of neoadjuvant immunotherapy

Induction options in the perioperative setting

A new standard of care for operated patients with eGFRmut adenocarcinoma

More options in the perioperative setting

Role of periopertative IO confirmed

Adjuvant and neoadjuvant strategies in resectable NSCLC

A new standard of care

An imperfect analysis, but perfect results

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

EGFR testing necessary in the adjuvant setting

ADAURA - results and controversies

CheckMate 9LA: 4‑year clinical update

A chemo-free preop. IO strategy?

Another neoadjuvant chemo/IO option

OS benefit from EGFR receptor TKI

ADAURA - Discussion closed?

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

Perioperative treatment

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Más opciones en el entorno perioperatorio

Rolle der periopertativen IO bestätigt

ADAURA- discussie gesloten?

TTF-treatment requires further studies

Zorifertinib: an option when osimertinib is not available

Sotorasib: clear clinical benefit, but short follow-up time

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Does ADC + chemo + IO replace the existing concepts?

Update on KRASG12Cm treatment options - how to proceed?

CORRELATE - a real world analysis

LUNAR: TTF medical device shows OS-benefit, but more information needed

ADC + ICI ± Pt-CT in patients with aNSCLC

IO in EGRF positive patients post TKI

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Stopping treatment is ok

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

Treatment strategies in SCLC

Hyperfractionated radiotherapy for SCLC

A positive trial with no impact

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

No practice-changing data in mesothelioma, other studies to await

Immune checkpoint inhibitors in malignant mesothelioma

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom